Travere Therapeutics, Inc. (TVTX)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
51.80 USD
-0.22
(-0.423%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 51.80 |
Hot Take ↕ | Oct. 10, 2026, 10:50 a.m. EDT
The narrative here is a classic biotech 'event-driven' setup centered on the FDA approval for Filspari. Fundamentally, the company is showing signs of life with nearly 50% revenue growth and a forward P/E of roughly 9x, which is attractive for a growth stock, though the balance sheet remains fragile with debt significantly exceeding cash. The market has rewarded this turnaround recently, pushing the stock up nearly 100% over the last year, yet the recent price action shows weakness relative to the 50-day moving average, creating a technical headwind despite the positive momentum. The options market confirms this tension: traders are hedging against a failure to rally further by placing heavy put walls near current prices, while still betting on a massive upside move later in the year. This is not a safe buy-and-hold yet; it is a high-risk, high-reward speculative play dependent entirely on the binary outcome of the regulatory approval. The statistical forecast models are too weak to guide a trade here, so the decision rests on whether you believe the drug will secure approval and drive the stock toward the $90 analyst targets. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.049055 |
| AutoARIMA | 0.063782 |
| MSTL | 0.094736 |
| AutoETS | 0.094934 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 2.64 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.128 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2515.721 |
| Revenue per Share | 6.482 |
| Market Cap | 4,817,032,192 |
| Forward P/E | 9.19 |
| Beta | 1.14 |
| Profit Margins | -7.35% |
| Previous Name | Retrophin, Inc. |
| Website | https://travere.com |
As of Oct. 10, 2026, 10:50 a.m. EDT: Speculators are positioning for a volatile range-bound scenario rather than a decisive breakout. Heavy open interest walls exist at $50 and $52.50 for both calls and puts, acting as magnets or barriers. While there is significant volume in deep out-of-the-money calls (strikes $85-$100) suggesting a long-term bullish thesis, the immediate term is dominated by put buying at strikes $40-$50, indicating a fear of a drop back to support levels. Implied volatility is elevated for near-term expirations, pricing in uncertainty around the upcoming FDA decision.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.99005353 |
| Address1 | 3,611 Valley Centre Drive |
| Address2 | Suite 300 |
| All Time High | 68.73 |
| All Time Low | 1.5 |
| Ask | 78.79 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,065,910 |
| Average Daily Volume3 Month | 1,592,303 |
| Average Volume | 1,592,303 |
| Average Volume10Days | 2,065,910 |
| Beta | 1.142 |
| Bid | 47.37 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 0.26 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 51.8 |
| Current Ratio | 4.046 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 52.81 |
| Day Low | 51.38 |
| Debt To Equity | 2,515.721 |
| Display Name | Travere Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda | 22,913,000 |
| Ebitda Margins | 0.03875 |
| Enterprise To Ebitda | 218.673 |
| Enterprise To Revenue | 8.473 |
| Enterprise Value | 5,010,451,968 |
| Eps Current Year | 1.69405 |
| Eps Forward | 5.63865 |
| Eps Trailing Twelve Months | -0.74 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 61.9455 |
| Fifty Day Average Change | -10.1455 |
| Fifty Day Average Change Percent | -0.16378108 |
| Fifty Two Week Change Percent | 99.005356 |
| Fifty Two Week High | 68.73 |
| Fifty Two Week High Change | -16.930004 |
| Fifty Two Week High Change Percent | -0.24632625 |
| Fifty Two Week Low | 22.59 |
| Fifty Two Week Low Change | 29.21 |
| Fifty Two Week Low Change Percent | 1.2930499 |
| Fifty Two Week Range | 22.59 - 68.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,385,000,000 |
| Float Shares | 93,031,917 |
| Forward Eps | 5.63865 |
| Forward P E | 9.186596 |
| Free Cashflow | -18,254,250 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 497 |
| Fullday Change | -0.22000122 |
| Fullday Change Percent | -0.42291662 |
| Fullday Price | 51.8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.59208 |
| Gross Profits | 350,115,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00694 |
| Held Percent Institutions | 1.15235 |
| Implied Shares Outstanding | 92,992,905 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California. |
| Long Name | Travere Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 4,817,032,192 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_133551169 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -67,679,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,637,755,314 |
| Number Of Analyst Opinions | 14 |
| Open | 51.57 |
| Operating Cashflow | 92,700,000 |
| Operating Margins | 0.02332 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 888 969 7879 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 51.8 |
| Post Market Time | 1,791,921,636 |
| Prev Name | Retrophin, Inc. |
| Previous Close | 52.02 |
| Price Eps Current Year | 30.57761 |
| Price Hint | 2 |
| Price To Book | 199.23077 |
| Price To Sales Trailing12 Months | 8.146098 |
| Profit Margins | -0.0735 |
| Quick Ratio | 3.763 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | -0.220001 |
| Regular Market Change Percent | -0.422917 |
| Regular Market Day High | 52.81 |
| Regular Market Day Low | 51.38 |
| Regular Market Day Range | 51.38 - 52.81 |
| Regular Market Open | 51.57 |
| Regular Market Previous Close | 52.02 |
| Regular Market Price | 51.8 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 1,668,577 |
| Return On Assets | -0.03733 |
| Return On Equity | -2.36355 |
| Revenue Growth | 0.482 |
| Revenue Per Share | 6.482 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 92,992,905 |
| Shares Percent Shares Out | 0.13430001 |
| Shares Short | 12,655,839 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 12,004,820 |
| Short Name | Travere Therapeutics, Inc. |
| Short Percent Of Float | 0.1748 |
| Short Ratio | 8.16 |
| Source Interval | 15 |
| State | CA |
| Symbol | TVTX |
| Target High Price | 90.0 |
| Target Low Price | 62.0 |
| Target Mean Price | 75.21429 |
| Target Median Price | 75.5 |
| Total Cash | 489,176,992 |
| Total Cash Per Share | 5.19 |
| Total Debt | 616,905,024 |
| Total Revenue | 591,329,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 45.56065 |
| Two Hundred Day Average Change | 6.2393494 |
| Two Hundred Day Average Change Percent | 0.13694601 |
| Type Disp | Equity |
| Volume | 1,668,577 |
| Website | https://travere.com |
| Zip | 92,130 |